A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis - Trial NCT06030076
Access comprehensive clinical trial information for NCT06030076 through Pure Global AI's free database. This phase not specified trial is sponsored by Almirall, S.A. and is currently Not yet recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Almirall, S.A.
Timeline & Enrollment
N/A
Sep 15, 2023
Jan 01, 2025
Primary Outcome
Treatment Satisfaction Questionnaire for Medication-11 (TSQM-11) Score,World Health Organisation Well-Being Index (WHO-5) Score
Summary
The main aim of this study is to assess the effects of switching from another biologic to
 tildrakizumab on patient-reported outcomes and to assess psoriasis intensity, patient's
 quality of life prior and after switching and the individual rationales for switching
 biologics.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06030076
Non-Device Trial